Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 6, 2013, Pages 1369-1374

  Ahmed, Tamer A ^a   Hayslip, John ^b,c   Leggas, Markos ^a,b  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

High dose; Leukemia; Pharmacokinetics; Simvastatin

Indexed keywords

ANTILIPEMIC AGENT; CARBOXYLIC ACID DERIVATIVE; LACTONE DERIVATIVE; SIMVASTATIN; SIMVASTATIN CARBOXYLATE; SIMVASTATIN LACTONE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIMB PAIN; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; MAXIMUM TOLERATED DOSE; PILOT PROJECTS; RECURRENCE; SIMVASTATIN; TANDEM MASS SPECTROMETRY;

EID: 84890431722     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2326-3     Document Type: Article

References (20)

1. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343(6257):425-430. doi: 10.1038/343425a0
2. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG (2007) Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discovery 6(7):541-555. doi: 10.1038/nrd2221
3. Crick DC, Andres DA, Danesi R, Macchia M, Waechter CJ (1998) Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. J Neurochem 70(6):2397-2405
4. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2001) Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 15(9):1398-1407
5. Sleijfer S, van der Gaast A, Planting AS, Stoter G, Verweij J (2005) The potential of statins as part of anti-cancer treatment. Eur J Cancer 41(4):516-522. doi: 10.1016/j.ejca.2004.12.009
6. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2(3):483-491
7. Larner J, Jane J, Laws E, Packer R, Myers C, Shaffrey M (1998) A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 21(6):579-583
8. van der Spek E, Bloem AC, van de Donk NW, Bogers LH, van der Griend R, Kramer MH, de Weerdt O, Wittebol S, Lokhorst HM (2006) Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica 91(4):542-545
9. van der Spek E, Bloem AC, Sinnige HA, Lokhorst HM (2007) High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma. Haematologica 92(12):e130-e131. doi: 10.3324/haematol.12071
10. Ahmed TA, Horn J, Hayslip J, Leggas M (2012) Validated LC-MS/MS method for simultaneous determination of SIM and its acid form in human plasma and cell lysate: pharmacokinetic application. J Pharma Anal 2(6):403-411. doi: 10.1016/j.jpha.2012.07.010
11. Kim J, Ahn BJ, Chae HS, Han S, Doh K, Choi J, Jun YK, Lee YW, Yim DS (2011) A population pharmacokinetic-pharmacodynamic model for simvastatin that predicts low-density lipoprotein-cholesterol reduction in patients with primary hyperlipidaemia. Basic Clin Pharmacol Toxicol 109(3):156-163. doi: 10.1111/j.1742-7843.2011.00700.x
12. Prueksaritanont T, Qiu Y, Mu L, Michel K, Brunner J, Richards KM, Lin JH (2005) Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. Pharm Res 22(7):1101-1109. doi: 10.1007/s11095-005-6037-2
13. Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, Moore MJ, Chin S, Irish J, LaFramboise S, Oza AM (2005) A phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer 41(4):523-530. doi: 10.1016/j.ejca.2004.12.013
14. Sondergaard TE, Pedersen PT, Andersen TL, Soe K, Lund T, Ostergaard B, Garnero P, Delaisse JM, Plesner T (2009) A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Hematol Oncol 27(1):17-22. doi: 10.1002/hon.869
15. Neuvonen PJ, Backman JT, Niemi M (2008) Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 47(7):463-474
16. Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ (2006) Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 57(2):155-164. doi: 10.1007/s00280-005-0013-8
17. Cemeus C, Zhao TT, Barrett GM, Lorimer IA, Dimitroulakos J (2008) Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neurooncol 90(1):9-17. doi: 10.1007/s11060-008-9627- 0
18. Wu H, Jiang H, Lu D, Xiong Y, Qu C, Zhou D, Mahmood A, Chopp M (2009) Effect of simvastatin on glioma cell proliferation, migration, and apoptosis. Neurosurgery 65(6):1087-1096; discussion 1096-1087. doi: 10.1227/01.NEU. 0000360130.52812.1D
19. van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC (2002) The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 16(7):1362-1371. doi: 10.1038/sj.leu.2402501
20. Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn JC (2000) Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res 20(4):2761-2771